MedPage Today contacted 13 rheumatologists to gauge their thoughts on what may be the most significant developments in arthritis in 2015. Some of the game changers the specialists were excited about, included:

  • Several JAK inhibitors, including baricitinib, are in varying stages of development and trial findings seem to have patients and specialists pleased for their potential.
  • For individuals with psoriatic arthritis, study findings show secukinumab efficacy rates are comparable to tumor necrosis factor inhibitors (anti-TNF agents).
  • As noted in the 2015 American College of Rheumatology guidelines, rheumatologists are excited about the possibility for patients in remission to cut down on medications, which can simplify therapy and lead to overall cost savings.

For the full list of developments in arthritis treatment in 2015, click here.